Dexcom's first quarter 2023 results showed strong revenue growth of 18% year-over-year, driven by volume growth and new customer additions. The company launched Dexcom G7 in the United States and finalized coverage with the US Centers for Medicare & Medicaid Services. The company raised its 2023 revenue guidance.
Revenue grew 18% versus the same quarter of the prior year to $741.5 million.
U.S. revenue growth of 17% and international revenue growth of 21%.
GAAP operating income of $47.2 million or 6.4% of revenue.
Initiated the launch of Dexcom G7 in the United States.
The company is updating fiscal year 2023 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels:
Visualization of income flow from segment revenue to net income